Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results

Neurosci Biobehav Rev. 2023 Nov:154:105421. doi: 10.1016/j.neubiorev.2023.105421. Epub 2023 Oct 5.

Abstract

Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. While fMRI is a promising tool for measuring brain function in response to psychedelics, it also has known methodological challenges. We conducted a systematic review of fMRI studies examining acute responses to experimentally administered psychedelics in order to identify convergent findings and characterize heterogeneity in the literature. We reviewed 91 full-text papers; these studies were notable for substantial heterogeneity in design, task, dosage, drug timing, and statistical approach. Data recycling was common, with 51 unique samples across 91 studies. Fifty-seven studies (54%) did not meet contemporary standards for Type I error correction or control of motion artifact. Psilocybin and LSD were consistently reported to moderate the connectivity architecture of the sensorimotor-association cortical axis. Studies also consistently reported that ketamine administration increased activation in the dorsomedial prefrontal cortex. Moving forward, use of best practices such as pre-registration, standardized image processing and statistical testing, and data sharing will be important in this rapidly developing field.

Keywords: FMRI; Functional magnetic resonance imaging; Ketamine; LSD; MDMA; Psilocybin; Psychedelics.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Brain / diagnostic imaging
  • Hallucinogens* / pharmacology
  • Humans
  • Ketamine* / pharmacology
  • N-Methyl-3,4-methylenedioxyamphetamine* / pharmacology
  • Psilocybin / pharmacology

Substances

  • Hallucinogens
  • Ketamine
  • N-Methyl-3,4-methylenedioxyamphetamine
  • Psilocybin